API
< Back to all clusters
[HEALTH] · Italy, United States · 16 sources

started · updated

Medical advancements target ALS and Myasthenia Gravis

Neurologist Neil Shneider of Columbia University reports that Amyotrophic Lateral Sclerosis (ALS) is becoming a treatable condition through personalized therapies. Research has focused on the 10% to 15% of cases caused by genetic mutations. Notable progress includes the drug tofersen for the Sod1 gene and positive results from the phase 3 Fusion study targeting the Fus gene, with results expected at an international symposium in 2027.

In a separate development, a new Policy Paper regarding Myasthenia Gravis was presented in Rome. The document, produced by the Myasthenia Gravis Alliance and the Rare Diseases Observatory, calls for more sustainable and personalized healthcare strategies. It emphasizes that evaluating new treatments for this autoimmune disorder must consider clinical efficacy alongside social impact and regional service organization to ensure equitable access to innovation.

Entities

Columbia University · Italy · Myasthenia Gravis Alliance · Neil Shneider · Osservatorio Malattie Rare · Rare Diseases Observatory · Rome · Ucb Pharma

Sources